The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bristol-Myers Squibb
Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; Harpoon therapeutics; Kleo Pharmaceuticals; Tizona Therapeutics, Inc.; Urogen pharma; Werewolf Therapeutics
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Compugen; F-Star; Ferring; Genocea Biosciences; Janssen Oncology; Kleo Pharmaceuticals; Merck; Merck Serono; Pfizer; Pierre Fabre; Roche/Genentech; Shattuck Labs; Tizona Therapeutics, Inc.; Urogen pharma; Werewolf Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Merck Sharp & Dohme; Pfizer; Roche/Genentech
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Sanofi; Sysmex; Vapotherm
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; CytomX Therapeutics; Merck; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); incyte; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Gulam Abbas Manji
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - Exelixis; Roche/Genentech
Research Funding - BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Nexus Pharmaceuticals Inc
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Biothera; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Helsinn Therapeutics; Incyte; Inivata; Loxo; Merck; Novartis; Peregrine Pharmaceuticals; Pfizer; Synta; Synta
Research Funding - Bristol-Myers Squibb
 
Brian S. Henick
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Boehringer Ingelheim
 
Matthew Ingham
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Apexigen (Inst); Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech; Mirati Therapeutics
 
Chih-Yi Liao
Consulting or Advisory Role - Exelixis; Incyte; Ipsen; Lexicon
Speakers' Bureau - Eisai; Exelixis
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Eisai; Exelixis; Incyte; Ipsen
 
Sameek Roychowdhury
Stock and Other Ownership Interests - Johnson & Johnson (I)
Consulting or Advisory Role - AbbVie; Incyte; Merck; QED Therapeutics
Research Funding - Ignyta; Incyte; QED Therapeutics; Takeda
 
Chrisann Kyi
No Relationships to Disclose
 
Paul Andrew Basciano
Employment - Bristol-Myers Squibb
 
Eirini Bournazou
No Relationships to Disclose
 
Jesse Abhyankar
Employment - Gritstone Bio
Stock and Other Ownership Interests - Gritstone Bio
 
Ashish Bezawada
Employment - Gritstone Bio
Stock and Other Ownership Interests - Gritstone Bio
 
Sonia Kounavouth
Employment - Gritstone Bio
Stock and Other Ownership Interests - Gritstone Bio
 
Desiree Schenk
Employment - Gritstone Bio
Stock and Other Ownership Interests - Gritstone Bio
 
Andrew R. Ferguson
Employment - Gritstone Bio
Stock and Other Ownership Interests - Gritstone Bio
 
Raphael F. Rousseau
Employment - Gritstone Bio
Leadership - Gritstone Bio
Stock and Other Ownership Interests - Allogene Therapeutics; Autolus; Gritstone Bio; Roche
 
Daniel V.T. Catenacci
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus